• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Prils Market Size

    ID: MRFR/HC/6223-CR
    153 Pages
    Kinjoll Dey
    April 2019

    Prils Market Research Report Information by Type (Ramipril, Quinapril, Cilazapril, & Benazepril), Application (Hypertension, Heart Failure, & Chronic Kidney Disorders), & Region (Americas, Europe, Asia-Pacific & the Middle East & Africa) - Global Forecast till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Prils Market Infographic

    Purchase Options

    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Summary Table of Contents Segmentation Download PDF

    Prils Size

    Prils Market Growth Projections and Opportunities

    The global prils market is all about active pharmaceutical ingredients (API), which are like the essential building blocks of medicines. These APIs are biologically active substances that play a crucial role in various medications. Different APIs have different properties, and they are used by the pharmaceutical, biotech, and nutritional industries to create new and effective products. The market is driven by several important factors, such as the increasing occurrence of heart diseases, hypertension, and kidney-related problems. Additionally, the growing population of older individuals, the rising importance of generic drugs, and the overall growth of the biopharmaceuticals industry contribute to the market's expansion. On the flip side, some challenges hinder the growth of the prils market. Unfavorable drug price control policies in many countries pose a challenge. There is also an increasing issue of counterfeit drugs entering the market, which can be harmful. Additionally, the complex procedures for renewing licenses can be a hurdle for market growth. Despite these challenges, the prils market continues to evolve and adapt to meet the needs of the pharmaceutical and related industries. Understanding the prils market involves recognizing the significance of APIs, which act as the active and essential components in medications. These APIs are vital in creating drugs that address various health issues, particularly those related to the heart, blood pressure, and kidneys. The demand for such medications is on the rise due to the increasing prevalence of health conditions and the growing aging population worldwide. One of the driving forces behind the growth of the prils market is the increasing incidence of heart diseases, hypertension, and kidney-related problems. These health issues have become more prevalent, necessitating the development of effective medications containing prils to address these concerns. The rise in the aging population is also a significant factor contributing to the market's expansion. As people age, they may experience various health issues, creating a demand for pharmaceutical products that contain prils.

    Prils Market Size Graph

    Market Summary

    The Global Prils Market is projected to grow from 3.15 USD Billion in 2024 to 5.72 USD Billion by 2035, reflecting a robust growth trajectory.

    Key Market Trends & Highlights

    Prils Key Trends and Highlights

    • The market is expected to achieve a compound annual growth rate (CAGR) of 5.58% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 5.72 USD Billion, indicating substantial growth potential.
    • In 2024, the market is valued at 3.15 USD Billion, laying a strong foundation for future expansion.
    • Growing adoption of innovative healthcare solutions due to increasing prevalence of chronic diseases is a major market driver.

    Market Size & Forecast

    2024 Market Size 3.15 (USD Billion)
    2035 Market Size 5.72 (USD Billion)
    CAGR (2025-2035) 5.58%
    Largest Regional Market Share in 2024 south_america)

    Major Players

    Lupin, Pfizer, Mylan N.V., F. Hoffman-L Roche, Novartis AG, Aurobindo Pharma, Sun Pharmaceuticals, Canadian Pharmaceuticals, Manus Aktteva Biopharma LLP, Hoffman La Roche, Boehringer Ingelheim International Gmbh, Teva Pharmaceutical Industries

    Market Trends

    The global Prils market appears to be experiencing a notable shift towards innovative formulations and personalized medicine, reflecting a growing demand for tailored therapeutic solutions.

    U.S. Food and Drug Administration (FDA)

    Prils Market Market Drivers

    Rising Demand for Pharmaceuticals

    The Global Prils Market Industry experiences a notable surge in demand driven by the increasing prevalence of hypertension and cardiovascular diseases. As healthcare systems worldwide prioritize the management of these conditions, the market for Prils is projected to reach 3.15 USD Billion in 2024. This growth is indicative of a broader trend where pharmaceutical companies are focusing on developing innovative formulations and delivery methods for Prils, thereby enhancing patient adherence and treatment outcomes. The emphasis on preventive healthcare further propels this demand, suggesting a robust future for the Global Prils Market Industry.

    Market Segment Insights

    Regional Insights

    Key Companies in the Prils Market market include

    Industry Developments

      • A global pharmaceutical company Hikal announced its approval by the U.S. Food and Drugs Administration (FDA). Hikal is developing and growing in the market gradually and steadily. It is expected to lead the prils market in forthcoming years.
      • The FDA in the United States of America played a crucial role in the increasing the sales worldwide. The organisation approved several drugs related to cardiovascular treatments. It helped the manufacturers to develop more drugs at a rapid speed and reach more patients in need.

    Future Outlook

    Prils Market Future Outlook

    The Global Prils Market is projected to grow at a 5.58% CAGR from 2024 to 2035, driven by increasing demand for effective antihypertensive treatments and advancements in pharmaceutical formulations.

    New opportunities lie in:

    • Develop innovative combination therapies to enhance efficacy and patient compliance.
    • Expand distribution channels in emerging markets to capture untapped consumer segments.
    • Invest in digital health solutions to improve patient monitoring and adherence.

    By 2035, the Global Prils Market is expected to achieve robust growth, reflecting evolving healthcare needs and technological advancements.

    Market Segmentation

    By Type

    • Cilazapril
    • Ramipril
    • Benazepril
    • Quinapril

    By Application

    • Others
    • Hypertension
    • Chronic Kidney Disorders
    • Heart Failure

    Recent Developments

    • The FDA in the United States of America played a crucial role in the increasing the sales worldwide. The organisation approved several drugs related to cardiovascular treatments. It helped the manufacturers to develop more drugs at a rapid speed and reach more patients in need.
    • A global pharmaceutical company Hikal announced its approval by the U.S. Food and Drugs Administration (FDA). Hikal is developing and growing in the market gradually and steadily. It is expected to lead the prils market in forthcoming years.

    By Geographical Region

    • The Middle East and Africa (GCC, South Africa, and rest)
    • Europe (Germany, France, Spain, Italy, U.K.)
    • Asia Pacific (India, Japan, China, Australia, and rest)
    • Latin America (Mexico, Brazil, and rest)
    • North America (The U.S. and Canada)

    Key Players in the Prils Market 

    • Teva Pharmaceutical Industries (U.S.)
    • Boehringer Ingelheim International Gmbh (Germany)
    • Hoffman La Roche (Switzerland)
    • Manus Aktteva Biopharma LLP (India)
    • Canadian Pharmaceuticals (Canada)
    • Novartis (Switzerland)
    • Sun Pharmaceuticals (India)
    • Pfizer (U.S.)
    • Aurobindo Pharma (India)
    • Lupin (India)
    • MERCK KGaA (Germany)
    • Mylan N.V. (U.S.)
    • The FDA in the United States of America played a crucial role in the increasing the sales worldwide. The organisation approved several drugs related to cardiovascular treatments. It helped the manufacturers to develop more drugs at a rapid speed and reach more patients in need.
    • A global pharmaceutical company Hikal announced its approval by the U.S. Food and Drugs Administration (FDA). Hikal is developing and growing in the market gradually and steadily. It is expected to lead the prils market in forthcoming years.

    Report Scope

    Report Attribute/Metric Details
      Market Size 2023   USD 2.95 Billion
      Market Size 2024   USD 3.15 Billion
      Market Size 2032   USD 4.93 Billion
    CAGR 5.10% (2024-2032)
    Base Year   2021
    Forecast Period   2024-2032
    Historical Data   2020
    Forecast Units   Value (USD Million)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Segments Covered Types, end user, Region
    Geographies Covered America, Europe, Asia Pacific, Middle East and Africa
    Key Vendors Mylan N.V. (U.S.), MERCK KGaA (Germany), Lupin (India), Aurobindo Pharma (India), Pfizer (U.S.), Sun Pharmaceuticals (India), Novartis (Switzerland), Canadian Pharmaceuticals (Canada), Manus Aktteva Biopharma LLP (India), Hoffman La Roche (Switzerland), Boehringer Ingelheim International Gmbh (Germany), Teva Pharmaceutical Industries (U.S.)

    Market Highlights

    Author

    Kinjoll Dey
    Research Analyst Level I

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM
    View All

    FAQs

    At what CAGR is the prils market projected to grow during the forecast period?

    Prils market is projected to grow at a 5.10% CAGR between 2024-2032.

    Which region is expected to dominate the prils market?

    The Americas is expected to dominate the prils market.

    What will be the value of the prils market during the forecast period?

    Prils market is predicted to touch USD 4.93 Billion by 2032.

    What are the major applications of prils?

    Prils are widely used for chronic kidney disorders, heart failure, and hypertension.

    Which factors may limit the prils market growth?

    Rise in counterfeit drugs may limit the prils market growth.

    1. Executive Summary
    2. Market Introduction
      1. Scope of the Study
      2. Research Objective 13
      3. List of Assumptions 14
    3. Research
      1. Research Process 15
      2. Primary Research 16
      3. Secondary
      4. Market Size Estimation 18
    4. Market Dynamics
      1. Introduction
      2. Drivers 20
        1. Growing Pharmaceutical Industry 20
        2. Growing Importance
      3. Restraints 21
        1. Stringent Regulatory Policies
        2. Adverse Drug Price Control Policies Across Numerous Countries 21
      4. Opportunity 22
        1. Development of New Drugs 22
      5. Product Pipeline
        1. Introduction 22
        2. NT-proBNP Selected Prevention
        3. Testing Ramipril to Prevent
        4. Ramipril Treatment of Claudication
        5. Bariatric Surgery and Pharmacokinetics of Ramipril 24
    5. Market
      1. Value Chain Analysis 25
        1. R&D and Designing
        2. Manufacturing 25
        3. Distribution & Sales 25
        4. Post-Sales Review 26
      2. Porter’s
        1. Bargaining Power of Suppliers 28
        2. Bargaining
        3. Threat of New Entrants 28
        4. Intense Rivalry
      3. Specifications & Purity Requirements 29
      4. Patent Analysis
        1. Introduction 30
      5. Regulatory Analysis 31
    6. Prils Market,
      1. Introduction 32
      2. Ramapril 34
      3. Quinapril 34
      4. Benazepril 35
    7. Prils Market, by Application
      1. Hypertension 37
      2. Heart Failure 38
      3. Chronic
    8. Global Prils Market, by Region
      1. Introduction
      2. Americas 41
        1. North America 43
        2. South America 46
      3. Europe 48
        1. Western Europe 50
      4. Asia-Pacific 59
        1. Japan 61
        2. China 62
        3. India 63
        4. Australia 64
        5. South Korea 65
        6. Rest of Asia-Pacific 66
      5. Middle East & Africa 68
        1. Middle East 70
        2. Africa 71
    9. Competitive landscape
      1. Introduction 72
      2. Key developments 72
    10. Company Profiles
      1. Company Overview 75
        1. Financial Overview
        2. Products/Services Offered 76
        3. Key Developments 76
        4. Key Strategies 77
      2. Lupin 78
        1. Company
        2. Financial Overview 78
        3. Products/Services Offered
        4. Key Developments 79
        5. SWOT Analysis 79
        6. Key
      3. Pfizer, Inc. 81
        1. Company Overview 81
        2. Products/Services Offered 82
        3. Key Developments
        4. SWOT Analysis 82
        5. Key Strategies 83
      4. Mylan N.V.
        1. Company Overview 84
        2. Financial Overview 84
        3. Key Developments 85
        4. SWOT Analysis
        5. Key Strategies 86
      5. F. Hoffmann-La Roche 87
        1. Company
        2. Financial Overview 87
        3. Products/Services Offered
        4. Key Developments 88
        5. SWOT Analysis 88
        6. Key
      6. Sun Pharmaceutical Industries Ltd 89
        1. Company
        2. Financial Overview 89
        3. Products/Services Offered
        4. Key Developments 90
        5. SWOT Analysis 90
        6. Key
      7. Merck KGaA 91
        1. Company Overview 91
        2. Products/Services Offered 92
        3. Key Developments
        4. SWOT Analysis 92
        5. Key Strategies 92
      8. Manus Aktteva
        1. Company Overview 93
        2. Financial Overview
        3. Products/Services Offered 93
        4. Key Developments 93
        5. Key Strategies 94
      9. Canagen Pharmaceuticals
        1. Company Overview 95
        2. Financial Overview 95
        3. Key Developments 95
        4. SWOT Analysis
        5. Key Strategies 96
      10. Novartis AG 97
        1. Company
        2. Financial Overview 97
        3. Products/Services Offered
        4. Key Developments 98
        5. SWOT Analysis 98
        6. Key
    11. Appendix
    12. List of Tables
    13. (USD MILLION) 35
    14. TO 2027 (USD MILLION) 35
    15. TO 2027 (USD MILLION) 36
    16. AMERICAS: PRILS MARKET, BY REGION, 2020 TO 2027 (USD MILLION) 41
    17. US: PRILS MARKET, BY TYPE, 2020 TO 2027 (USD MILLION) 44
    18. TO 2027 (VOLUME PER UNIT) 49
    19. TO 2027 (USD MILLION) 49
    20. TO 2027 (USD MILLION) 50
    21. TO 2027 (USD MILLION) 51
    22. TO 2027 (USD MILLION) 51
    23. ITALY: PRILS MARKET, BY APPLICATION, 2020 TO 2027 (USD MILLION) 55
    24. SPAIN: PRILS MARKET, BY TYPE, 2020 TO 2027 (USD MILLION) 56
    25. REST OF WESTERN EUROPE: PRILS MARKET, BY APPLICATION, 2020 TO 2027 (USD MILLION)
    26. INDIA: PRILS MARKET, BY APPLICATION, 2020 TO 2027 (USD MILLION) 64
    27. AUSTRALIA: PRILS MARKET, BY TYPE, 2020 TO 2027 (USD MILLION) 64
    28. SOUTH KOREA: PRILS MARKET, BY TYPE, 2020 TO 2027 (USD MILLION) 65
    29. SOUTH KOREA: PRILS MARKET, BY APPLICATION, 2020 TO 2027 (USD MILLION) 66
    30. REST OF ASIA-PACIFIC: PRILS MARKET, BY TYPE, 2020 TO 2027 (USD MILLION) 66
    31. List of Figures
    32. & 2027 (USD MILLION) 33
    33. & 2027 (USD MILLION) 37
    34. (%) 40
    35. EUROPE: PRILS MARKET SHARE, BY REGION, 2020 (%) 48

    Prils Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Related Reports

    Regional Reports
    Country Reports

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials
    Global Magnesium Sulfate Market – Forecast till 2027